人参皂苷Rg3对EMs患者免疫功能的影响

Influence of ginsenoside Rg3 on immune function of patients with endometriosis

目的比较人参皂苷Rg3与孕三烯酮联合手术对Ⅲ～Ⅳ期子宫内膜异位症（EMs）患者免疫功能的影响。方法将100例经腹腔镜手术后Ⅲ～Ⅳ期子宫内膜异位症患者分为两组：研究组50例，口服人参皂苷Rg320mg／次，1次／日，连用3个月；对照组为50例，口服孕三烯酮2．5mg/次，2次／周，连用3个月。分别于术后1个月及3个月检测T细胞亚群含量及白介素-6含量。结果研究组血清CD3’、CD3＋CD8＋、CD4＋／CD8＋比率在用药治疗1个月及3个月时比术前明显上升，与对照纽相比差异有统计学意义（F值分别为15．877、6．437、4．227、51．956、42．366、32．788，均P〈0．05）。研究组血清CD3＋CD4＋比率及白介素-6在用药治疗1个月及3个月时比术前明显下降，与对照组相比差异有统计学意义（F值分别为19．289、39．197、6．383、147．432，均P〈0．05）。结论人参皂苷Rg3对改善子宫内膜异位症患者的免疫功能较孕三烯酮明显，是临床上子宫内膜异位症患者手术后的辅助药物。

Objective To compare the influence of ginsenoside Rg3 with that of gestrinone combined with surgery on immune function of patients with stage Ⅲ～Ⅳ endometriosis （EMs）. Methods A cohort of 100 conservative surgery patients with stage Ⅲ～Ⅳ EMs were assigned into two groups： study group （n = 50） receiving ginsenoside Rg3 therapy （20mg, orally, once daily） for 3 successive months, and control group （n = 50） treated with gestrinone （2.5mg, orally, twice weekly） for 3 successive months, respectively. The level of T cell subsets and interleukin-6 （IL-6） were detected 1 month and 3 months after surgery. Results Study group was noted with obviously elevated serum CD3 ＋T cell, CD3 ＋ CD8 ＋T cell, CD4 ＋/CD8 ＋ ratio at 1 month and 3 months after treatment compared with those before surgery, and the differences between study group and control group were significant （ F value was 15. 877, 6. 437, 4. 227, 51. 956, 42. 366 and 32. 788, respectively, all P 〈 0.05 ）. At 1 month and 3 months after surgery, CD3 ＋ CD4＋ ratio and IL-6 of study group decreased remarkably, and the differences between two groups were significant （F value was 19. 289, 39. 197, 6. 383 and 147. 432, respectively, all P 〈 0.05 ）. Conclusion Compared with gestrinone, ginsenoside Rg3 achieves higher efficacy in improving the immune function of EMs patients, and it is clinically effective adjuvant medication for patients with Ems.